Literature DB >> 29802205

Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis.

Reinhard J Sauter1,2, Manuela Sauter2, Edimara S Reis3, Frederic N Emschermann2, Henry Nording1,2, Sonja Ebenhöch2, Peter Kraft4, Patrick Münzer1, Maximilian Mauler5, Johannes Rheinlaender6, Johannes Madlung7, Frank Edlich8,9,10, Tilman E Schäffer6, Sven G Meuth11, Daniel Duerschmied5, Tobias Geisler1, Oliver Borst1, Meinrad Gawaz1, Christoph Kleinschnitz12, John D Lambris3, Harald F Langer1,2.   

Abstract

BACKGROUND: Platelets have distinct roles in the vascular system in that they are the major mediator of thrombosis, critical for restoration of tissue integrity, and players in vascular inflammatory conditions. In close spatiotemporal proximity, the complement system acts as the first line of defense against invading microorganisms and is a key mediator of inflammation. Whereas the fluid phase cross-talk between the complement and coagulation systems is well appreciated, the understanding of the pathophysiological implications of such interactions is still scant.
METHODS: We analyzed coexpression of the anaphylatoxin receptor C3aR with activated glycoprotein IIb/IIIa on platelets of 501 patients with coronary artery disease using flow cytometry; detected C3aR expression in human or murine specimen by polymerase chain reaction, immunofluorescence, Western blotting, or flow cytometry; and examined the importance of platelet C3aR by various in vitro platelet function tests, in vivo bleeding time, and intravital microscopy. The pathophysiological relevance of C3aR was scrutinized with the use of disease models of myocardial infarction and stroke. To approach underlying molecular mechanisms, we identified the platelet small GTPase Rap1b using nanoscale liquid chromatography coupled to tandem mass spectrometry.
RESULTS: We found a strong positive correlation of platelet complement C3aR expression with activated glycoprotein IIb/IIIa in patients with coronary artery disease and coexpression of C3aR with glycoprotein IIb/IIIa in thrombi obtained from patients with myocardial infarction. Our results demonstrate that the C3a/C3aR axis on platelets regulates distinct steps of thrombus formation such as platelet adhesion, spreading, and Ca2+ influx. Using C3aR-/- mice or C3-/- mice with reinjection of C3a, we uncovered that the complement activation fragment C3a regulates bleeding time after tail injury and thrombosis. Notably, C3aR-/- mice were less prone to experimental stroke and myocardial infarction. Furthermore, reconstitution of C3aR-/- mice with C3aR+/+ platelets and platelet depletion experiments demonstrated that the observed effects on thrombosis, myocardial infarction, and stroke were specifically caused by platelet C3aR. Mechanistically, C3aR-mediated signaling regulates the activation of Rap1b and thereby bleeding arrest after injury and in vivo thrombus formation.
CONCLUSIONS: Overall, our findings uncover a novel function of the anaphylatoxin C3a for platelet function and thrombus formation, highlighting a detrimental role of imbalanced complement activation in cardiovascular diseases.

Entities:  

Keywords:  anaphylatoxins; blood platelets; complement system proteins; inflammation; myocardial infarction; stroke; thrombosis

Mesh:

Substances:

Year:  2018        PMID: 29802205      PMCID: PMC6202244          DOI: 10.1161/CIRCULATIONAHA.118.034600

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  59 in total

1.  Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

Authors:  Paul W Armstrong; Christopher B Granger; Peter X Adams; Christian Hamm; David Holmes; William W O'Neill; Thomas G Todaro; Alec Vahanian; Frans Van de Werf
Journal:  JAMA       Date:  2007-01-03       Impact factor: 56.272

Review 2.  Role of C5a in inflammatory responses.

Authors:  Ren-Feng Guo; Peter A Ward
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

3.  Reevaluation of the C3a active site using short synthetic C3a analogues.

Authors:  J Köhl; M Casaretto; M Gier; G Karwath; C Gietz; W Bautsch; D Saunders; D Bitter-Suermann
Journal:  Eur J Immunol       Date:  1990-07       Impact factor: 5.532

4.  Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass.

Authors:  J C Fitch; S Rollins; L Matis; B Alford; S Aranki; C D Collard; M Dewar; J Elefteriades; R Hines; G Kopf; P Kraker; L Li; R O'Hara; C Rinder; H Rinder; R Shaw; B Smith; G Stahl; S K Shernan
Journal:  Circulation       Date:  1999 Dec 21-28       Impact factor: 29.690

Review 5.  Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Authors:  Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

Review 6.  Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment.

Authors:  Guido Stoll; Christoph Kleinschnitz; Bernhard Nieswandt
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

7.  Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).

Authors:  Gurpanna Saggu; Claudio Cortes; Heather N Emch; Galia Ramirez; Randall G Worth; Viviana P Ferreira
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

8.  Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice.

Authors:  Daisuke Ishida; Kohei Kometani; Hailin Yang; Kiyokazu Kakugawa; Kyoko Masuda; Kazuhiro Iwai; Misao Suzuki; Shigeyoshi Itohara; Tatsutoshi Nakahata; Hiroshi Hiai; Hiroshi Kawamoto; Masakazu Hattori; Nagahiro Minato
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

9.  Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets.

Authors:  Mark K Larson; Hong Chen; Mark L Kahn; Anne M Taylor; Jean-Etienne Fabre; Richard M Mortensen; Pamela B Conley; Leslie V Parise
Journal:  Blood       Date:  2002-10-17       Impact factor: 22.113

10.  Complement peptide C3a stimulates neural plasticity after experimental brain ischaemia.

Authors:  Anna Stokowska; Alison L Atkins; Javier Morán; Tulen Pekny; Linda Bulmer; Michaela C Pascoe; Scott R Barnum; Rick A Wetsel; Jonas A Nilsson; Mike Dragunow; Marcela Pekna
Journal:  Brain       Date:  2016-12-12       Impact factor: 13.501

View more
  34 in total

1.  Safety profile after prolonged C3 inhibition.

Authors:  Edimara S Reis; Nadja Berger; Xin Wang; Sophia Koutsogiannaki; Robert K Doot; Justin T Gumas; Periklis G Foukas; Ranillo R G Resuello; Joel V Tuplano; David Kukis; Alice F Tarantal; Anthony J Young; Tetsuhiro Kajikawa; Athena M Soulika; Dimitrios C Mastellos; Despina Yancopoulou; Ali-Reza Biglarnia; Markus Huber-Lang; George Hajishengallis; Bo Nilsson; John D Lambris
Journal:  Clin Immunol       Date:  2018-10-10       Impact factor: 3.969

Review 2.  Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.

Authors:  Shruti Chaturvedi; Evan M Braunstein; Robert A Brodsky
Journal:  J Thromb Haemost       Date:  2021-02-10       Impact factor: 5.824

3.  Bothrops lanceolatus snake (Fer-de-lance) venom triggers inflammatory mediators' storm in human blood.

Authors:  Felipe Silva de França; Joel José Megale Gabrili; Laurence Mathieu; François Burgher; Joël Blomet; Denise V Tambourgi
Journal:  Arch Toxicol       Date:  2021-01-04       Impact factor: 5.153

4.  Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.

Authors:  Panagiotis Skendros; Alexandros Mitsios; Akrivi Chrysanthopoulou; Dimitrios C Mastellos; Simeon Metallidis; Petros Rafailidis; Maria Ntinopoulou; Eleni Sertaridou; Victoria Tsironidou; Christina Tsigalou; Maria Tektonidou; Theocharis Konstantinidis; Charalampos Papagoras; Ioannis Mitroulis; Georgios Germanidis; John D Lambris; Konstantinos Ritis
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 5.  Patrolling the vascular borders: platelets in immunity to infection and cancer.

Authors:  Florian Gaertner; Steffen Massberg
Journal:  Nat Rev Immunol       Date:  2019-08-13       Impact factor: 53.106

6.  Adipsin deficiency does not impact atherosclerosis development in Ldlr-/- mice.

Authors:  Longhua Liu; Michelle Chan; Lexiang Yu; Weidong Wang; Li Qiang
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-11-02       Impact factor: 4.310

Review 7.  Interplay between inflammation and thrombosis in cardiovascular pathology.

Authors:  Konstantin Stark; Steffen Massberg
Journal:  Nat Rev Cardiol       Date:  2021-05-06       Impact factor: 32.419

Review 8.  Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity.

Authors:  Milka Koupenova; Alison C Livada; Craig N Morrell
Journal:  Circ Res       Date:  2022-01-20       Impact factor: 17.367

Review 9.  Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.

Authors:  Krishna Sriram; Paul A Insel
Journal:  Physiol Rev       Date:  2020-10-30       Impact factor: 37.312

10.  Complement activation on endothelium initiates antibody-mediated acute lung injury.

Authors:  Simon J Cleary; Nicholas Kwaan; Jennifer J Tian; Daniel R Calabrese; Beñat Mallavia; Mélia Magnen; John R Greenland; Anatoly Urisman; Jonathan P Singer; Steven R Hays; Jasleen Kukreja; Ariel M Hay; Heather L Howie; Pearl Toy; Clifford A Lowell; Craig N Morrell; James C Zimring; Mark R Looney
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.